0
Deep & Emerging Tech·November 11, 2026·1 min read

A Startup Wants to Fight AI Bioweapons With AI

Share

An offline model that claims to distinguish natural from engineered pathogens is a sign that AI-bio risk mitigation is becoming its own product category, not just a policy debate. If you touch biotech, cloud biology, or lab infrastructure, expect regulators and partners to start asking what defensive models you have in the loop.

Deep & Emerging Tech

OKX and ICE's joint venture OKXICE plans to launch a US tokenized stock venue on November 23 and list 70+ assets; 56 of the 62 companies it targeted objected

Tokenized equities are running straight into issuer resistance—56 of 62 targeted companies objected—which means the near-term action will be in regulatory arbitrage and niche assets, not blue-chip stocks. If you’re a broker or exchange operator, treat tokenization as an infrastructure experiment for now, not a core revenue line.